Validation of biomarkers of CVD risk from Dried blood spots in community-based research

Methodologies and study-specific serum equivalencies

Laura B. Samuelsson, Martica H. Hall, Shakir McLean, James H. Porter, Lisa Berkman, Miguel Marino, Grace Sembajwe, Thomas W. McDade, Orfeu M. Buxton

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Dried blood spot (DBS) methodology offers significant advantages over venipuncture in studies of vulnerable populations or large-scale studies, including reduced participant burden and higher response rates. Uncertainty about the validity of cardiovascular disease (CVD) risk biomarkers remains a barrier to wide-scale use. We determined the validity of DBS-derived biomarkers of CVD risk versus gold-standard assessments, and study-specific, serum-equivalency values for clinical relevance of DBS-derived values. Concurrent venipuncture serum and DBS samples (n = 150 adults) were assayed in Clinical Laboratory Improvement Amendments-certified and DBS laboratories, respectively. Time controls of DBS standard samples were assayed single-blind along with test samples. Linear regression analyses evaluated DBS-to-serum equivalency values; agreement and bias were assessed via Bland-Altman plots. Linear regressions of venipuncture values on DBS-to-serum equivalencies provided R2 values for total cholesterol, high-density lipoprotein cholesterol (HDL-C), and C-reactive protein (CRP) of 0.484, 0.118, and 0.666, respectively. Bland-Altman plots revealed minimal systematic bias between DBS-to-serum and venipuncture values; precision worsened at higher mean values of CRP. Time controls revealed little degradation or change in analyte values for HDL-C and CRP over 30 weeks. We concluded that DBS-assessed biomarkers represent a valid alternative to venipuncture assessments. Large studies using DBS should include study-specific serum-equivalency determinations to optimize individual-level sensitivity, the viability of detecting intervention effects, and generalizability in community-level primary prevention interventions.

Original languageEnglish (US)
Pages (from-to)285-297
Number of pages13
JournalBiodemography and Social Biology
Volume61
Issue number3
DOIs
StatePublished - Jan 1 2015

Fingerprint

cardiovascular disease
research methods
blood serum
cardiovascular diseases
biomarker
serum
biomarkers
Research Design
Cardiovascular Diseases
Biomarkers
blood
Disease
Phlebotomy
methodology
Serum
community
Values
C-reactive protein
C-Reactive Protein
HDL Cholesterol

ASJC Scopus subject areas

  • Genetics
  • Ecology, Evolution, Behavior and Systematics
  • Demography
  • Anthropology

Cite this

Validation of biomarkers of CVD risk from Dried blood spots in community-based research : Methodologies and study-specific serum equivalencies. / Samuelsson, Laura B.; Hall, Martica H.; McLean, Shakir; Porter, James H.; Berkman, Lisa; Marino, Miguel; Sembajwe, Grace; McDade, Thomas W.; Buxton, Orfeu M.

In: Biodemography and Social Biology, Vol. 61, No. 3, 01.01.2015, p. 285-297.

Research output: Contribution to journalArticle

Samuelsson, Laura B. ; Hall, Martica H. ; McLean, Shakir ; Porter, James H. ; Berkman, Lisa ; Marino, Miguel ; Sembajwe, Grace ; McDade, Thomas W. ; Buxton, Orfeu M. / Validation of biomarkers of CVD risk from Dried blood spots in community-based research : Methodologies and study-specific serum equivalencies. In: Biodemography and Social Biology. 2015 ; Vol. 61, No. 3. pp. 285-297.
@article{e07dda145fef4c67bc816a2e0100ccfb,
title = "Validation of biomarkers of CVD risk from Dried blood spots in community-based research: Methodologies and study-specific serum equivalencies",
abstract = "Dried blood spot (DBS) methodology offers significant advantages over venipuncture in studies of vulnerable populations or large-scale studies, including reduced participant burden and higher response rates. Uncertainty about the validity of cardiovascular disease (CVD) risk biomarkers remains a barrier to wide-scale use. We determined the validity of DBS-derived biomarkers of CVD risk versus gold-standard assessments, and study-specific, serum-equivalency values for clinical relevance of DBS-derived values. Concurrent venipuncture serum and DBS samples (n = 150 adults) were assayed in Clinical Laboratory Improvement Amendments-certified and DBS laboratories, respectively. Time controls of DBS standard samples were assayed single-blind along with test samples. Linear regression analyses evaluated DBS-to-serum equivalency values; agreement and bias were assessed via Bland-Altman plots. Linear regressions of venipuncture values on DBS-to-serum equivalencies provided R2 values for total cholesterol, high-density lipoprotein cholesterol (HDL-C), and C-reactive protein (CRP) of 0.484, 0.118, and 0.666, respectively. Bland-Altman plots revealed minimal systematic bias between DBS-to-serum and venipuncture values; precision worsened at higher mean values of CRP. Time controls revealed little degradation or change in analyte values for HDL-C and CRP over 30 weeks. We concluded that DBS-assessed biomarkers represent a valid alternative to venipuncture assessments. Large studies using DBS should include study-specific serum-equivalency determinations to optimize individual-level sensitivity, the viability of detecting intervention effects, and generalizability in community-level primary prevention interventions.",
author = "Samuelsson, {Laura B.} and Hall, {Martica H.} and Shakir McLean and Porter, {James H.} and Lisa Berkman and Miguel Marino and Grace Sembajwe and McDade, {Thomas W.} and Buxton, {Orfeu M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1080/19485565.2015.1068105",
language = "English (US)",
volume = "61",
pages = "285--297",
journal = "Biodemography and Social Biology",
issn = "1948-5565",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Validation of biomarkers of CVD risk from Dried blood spots in community-based research

T2 - Methodologies and study-specific serum equivalencies

AU - Samuelsson, Laura B.

AU - Hall, Martica H.

AU - McLean, Shakir

AU - Porter, James H.

AU - Berkman, Lisa

AU - Marino, Miguel

AU - Sembajwe, Grace

AU - McDade, Thomas W.

AU - Buxton, Orfeu M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Dried blood spot (DBS) methodology offers significant advantages over venipuncture in studies of vulnerable populations or large-scale studies, including reduced participant burden and higher response rates. Uncertainty about the validity of cardiovascular disease (CVD) risk biomarkers remains a barrier to wide-scale use. We determined the validity of DBS-derived biomarkers of CVD risk versus gold-standard assessments, and study-specific, serum-equivalency values for clinical relevance of DBS-derived values. Concurrent venipuncture serum and DBS samples (n = 150 adults) were assayed in Clinical Laboratory Improvement Amendments-certified and DBS laboratories, respectively. Time controls of DBS standard samples were assayed single-blind along with test samples. Linear regression analyses evaluated DBS-to-serum equivalency values; agreement and bias were assessed via Bland-Altman plots. Linear regressions of venipuncture values on DBS-to-serum equivalencies provided R2 values for total cholesterol, high-density lipoprotein cholesterol (HDL-C), and C-reactive protein (CRP) of 0.484, 0.118, and 0.666, respectively. Bland-Altman plots revealed minimal systematic bias between DBS-to-serum and venipuncture values; precision worsened at higher mean values of CRP. Time controls revealed little degradation or change in analyte values for HDL-C and CRP over 30 weeks. We concluded that DBS-assessed biomarkers represent a valid alternative to venipuncture assessments. Large studies using DBS should include study-specific serum-equivalency determinations to optimize individual-level sensitivity, the viability of detecting intervention effects, and generalizability in community-level primary prevention interventions.

AB - Dried blood spot (DBS) methodology offers significant advantages over venipuncture in studies of vulnerable populations or large-scale studies, including reduced participant burden and higher response rates. Uncertainty about the validity of cardiovascular disease (CVD) risk biomarkers remains a barrier to wide-scale use. We determined the validity of DBS-derived biomarkers of CVD risk versus gold-standard assessments, and study-specific, serum-equivalency values for clinical relevance of DBS-derived values. Concurrent venipuncture serum and DBS samples (n = 150 adults) were assayed in Clinical Laboratory Improvement Amendments-certified and DBS laboratories, respectively. Time controls of DBS standard samples were assayed single-blind along with test samples. Linear regression analyses evaluated DBS-to-serum equivalency values; agreement and bias were assessed via Bland-Altman plots. Linear regressions of venipuncture values on DBS-to-serum equivalencies provided R2 values for total cholesterol, high-density lipoprotein cholesterol (HDL-C), and C-reactive protein (CRP) of 0.484, 0.118, and 0.666, respectively. Bland-Altman plots revealed minimal systematic bias between DBS-to-serum and venipuncture values; precision worsened at higher mean values of CRP. Time controls revealed little degradation or change in analyte values for HDL-C and CRP over 30 weeks. We concluded that DBS-assessed biomarkers represent a valid alternative to venipuncture assessments. Large studies using DBS should include study-specific serum-equivalency determinations to optimize individual-level sensitivity, the viability of detecting intervention effects, and generalizability in community-level primary prevention interventions.

UR - http://www.scopus.com/inward/record.url?scp=84964432718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964432718&partnerID=8YFLogxK

U2 - 10.1080/19485565.2015.1068105

DO - 10.1080/19485565.2015.1068105

M3 - Article

VL - 61

SP - 285

EP - 297

JO - Biodemography and Social Biology

JF - Biodemography and Social Biology

SN - 1948-5565

IS - 3

ER -